Back to Journals » OncoTargets and Therapy » Volume 6

Palliative systemic therapy for women with recurrent epithelial ovarian cancer: current options

Authors Elit L, Hirte H

Received 6 November 2012

Accepted for publication 14 December 2012

Published 26 February 2013 Volume 2013:6 Pages 107—118


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Laurie Elit,1,2 Hal Hirte2

1Department of Obstetrics and Gynecology, McMaster University, Hamilton, Ontario, Canada; 2Department of Oncology, McMaster University, Hamilton, Ontario, Canada

Objectives: To review the available systemic treatments for women with recurrent ovarian cancer.
Methods: A literature review was conducted for recurrent ovarian cancer articles in English, including randomized trials, Phase II trials, or reviews.
Results: We discuss the efficacy and toxicity outcomes associated with systemic therapy for platinum-sensitive and platinum-resistant ovarian cancer. Clearly, platinum-based combination systemic therapy shows a prolonged progression-free interval compared with single-agent chemotherapy with a low toxicity profile. No clear superior management strategy exists for platinum-resistant/refractory disease. Novel targeted antiangiogenic agents (eg, bevacizumab), angiopoeitin inhibitors (eg, AMG 386), and poly ADP ribose polymerase inhibitors (eg, olaparib) are reviewed.
Conclusion: Although combination platinum-based chemotherapy has shown benefits for women with platinum-sensitive recurrent ovarian cancer, the optimal treatment strategy for those with platinum-resistant or platinum-refractory disease is not clear. Molecular and genetic targeted therapies may provide opportunities for those women with tumor profiles that show sensitivity for specific agents.

Keywords: ovarian cancer, systemic therapy, biologic agents

Creative Commons License © 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.